...
首页> 外文期刊>Toxicology and Applied Pharmacology >Anti-diabetic action of Punica granatum flower extract: activation of PPAR-gamma and identification of an active component.
【24h】

Anti-diabetic action of Punica granatum flower extract: activation of PPAR-gamma and identification of an active component.

机译:Punica granatum花提取物的抗糖尿病作用:激活PPAR-γ和鉴定活性成分。

获取原文
获取原文并翻译 | 示例

摘要

Peroxisome proliferator-activated receptor (PPAR)-gamma activators are widely used in the treatment of type 2 diabetes because they improve the sensitivity of insulin receptors. Punica granatum flower (PGF) has been used as an anti-diabetic medicine in Unani medicinal literature. The mechanism of actions is, however, unknown. In the current study, we demonstrated that 6-week oral administration of methanol extract from PGF (500 mg/kg, daily) inhibited glucose loading-induced increase of plasma glucose levels in Zucker diabetic fatty rats (ZDF), a genetic animal model for type 2 diabetes, whereas it did not inhibit the increase in Zucker lean rats (ZL). The treatment did not lower the plasma glucose levels in fasted ZDF and ZL rats. Furthermore, RT-PCR results demonstrated that the PGF extract treatment in ZDF rats enhanced cardiac PPAR-gamma mRNA expression and restored the down-regulated cardiac glucose transporter (GLUT)-4 (the insulin-dependent isoform of GLUTs) mRNA. These results suggest that the anti-diabetic activity of PGF extract may result from improved sensitivity of the insulin receptor. From the in vitro studies, we demonstrated that the PGF extract enhanced PPAR-gamma mRNA and protein expression and increased PPAR-gamma-dependent mRNA expression and activity of lipoprotein lipase in human THP-1-differentiated macrophage cells. Phytochemical investigation demonstrated that gallic acid in PGF extract is mostly responsible for this activity. Thus, our findings indicate that PPAR-gamma is a molecular target for PGF extract and its prominent component gallic acid, and provide a better understanding of the potential mechanism of the anti-diabetic action of PGF.
机译:过氧化物酶体增殖物激活受体(PPAR)-γ激活剂由于可提高胰岛素受体的敏感性而被广泛用于2型糖尿病的治疗。石榴花(PGF)在Unani的医学文献中已被用作抗糖尿病药。但是,作用机理尚不清楚。在当前的研究中,我们证明了口服PGF的甲醇提取物(500 mg / kg,每天)6周口服抑制了Zucker糖尿病脂肪大鼠(ZDF)的葡萄糖负荷诱导的血浆葡萄糖水平的升高,ZDF是一种遗传动物模型。 2型糖尿病,但它并未抑制Zucker瘦大鼠(ZL)的增加。该治疗并未降低禁食ZDF和ZL大鼠的血浆葡萄糖水平。此外,RT-PCR结果表明,ZDF大鼠的PGF提取物处理增强了心脏PPAR-γmRNA的表达,并恢复了下调的心脏葡萄糖转运蛋白(GLUT)-4(GLUTs的胰岛素依赖性亚型)mRNA。这些结果表明,PGF提取物的抗糖尿病活性可能是由于胰岛素受体的敏感性提高所致。从体外研究中,我们证明了PGF提取物在人THP-1分化的巨噬细胞中增强了PPAR-γmRNA和蛋白表达,并增加了PPAR-γ依赖性mRNA表达和脂蛋白脂肪酶活性。植物化学研究表明,PGF提取物中的没食子酸是造成这种活性的主要原因。因此,我们的发现表明,PPAR-γ是PGF提取物及其主要成分没食子酸的分子靶标,并提供了对PGF的抗糖尿病作用的潜在机制的更好理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号